Durable SARS-CoV-2 B cell immunity after mild or severe disease.
Ogega CO, Skinner NE, Blair PW, Park HS, Littlefield K, Ganesan A, Dhakal S, Ladiwala P, Antar AA, Ray SC, Betenbaugh MJ, Pekosz A, Klein SL, Manabe YC, Cox AL, Bailey JR.
Ogega CO, et al. Among authors: cox al.
J Clin Invest. 2021 Apr 1;131(7):e145516. doi: 10.1172/JCI145516.
J Clin Invest. 2021.
PMID: 33571162
Free PMC article.